Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population
Alzheimer's disease (AD) is a neurodegenerative disease, in which an accumulation of toxic amyloid beta in the brain precedes the emergence of clinical symptoms. AD spectrum consists of presymptomatic, early symptomatic, and symptomatic phase of dementia. At present, no pharmacotherapy exists t...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Journal of Postgraduate Medicine |
Subjects: | |
Online Access: | http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2016;volume=62;issue=4;spage=242;epage=248;aulast=Rygiel |
id |
doaj-ec44c306800443368541c65c841cf600 |
---|---|
record_format |
Article |
spelling |
doaj-ec44c306800443368541c65c841cf6002020-11-24T22:01:52ZengWolters Kluwer Medknow PublicationsJournal of Postgraduate Medicine0022-38590972-28232016-01-0162424224810.4103/0022-3859.188553Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient populationK RygielAlzheimer's disease (AD) is a neurodegenerative disease, in which an accumulation of toxic amyloid beta in the brain precedes the emergence of clinical symptoms. AD spectrum consists of presymptomatic, early symptomatic, and symptomatic phase of dementia. At present, no pharmacotherapy exists to modify or reverse a course of AD, and only symptomatic treatments are available. Many elderly patients, diagnosed with multiple medical conditions (such as cardiovascular diseases, Type 2 diabetes mellitus, and cerebrovascular diseases) are at increased risk of the development of mild cognitive impairment (MCI), AD, and vascular dementia. Studies have revealed reduced rates of cognitive decline, in elderly patients, who were treated with centrally active angiotensin-converting enzyme inhibitors (ACE-Is) (that have an ability to cross the blood–brain barrier). This article reviews recently published literature, focused on possible protective influence of the centrally active ACE-Is, in the elderly population, at risk for cognitive decline.http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2016;volume=62;issue=4;spage=242;epage=248;aulast=RygielAlzheimer's diseaseangiotensin.converting enzyme inhibitorsmild cognitive impairmentrenin.angiotensin system |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
K Rygiel |
spellingShingle |
K Rygiel Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population Journal of Postgraduate Medicine Alzheimer's disease angiotensin.converting enzyme inhibitors mild cognitive impairment renin.angiotensin system |
author_facet |
K Rygiel |
author_sort |
K Rygiel |
title |
Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population |
title_short |
Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population |
title_full |
Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population |
title_fullStr |
Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population |
title_full_unstemmed |
Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population |
title_sort |
can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of alzheimer's disease? an overview of research evidence in the elderly patient population |
publisher |
Wolters Kluwer Medknow Publications |
series |
Journal of Postgraduate Medicine |
issn |
0022-3859 0972-2823 |
publishDate |
2016-01-01 |
description |
Alzheimer's disease (AD) is a neurodegenerative disease, in which an accumulation of toxic amyloid beta in the brain precedes the emergence of clinical symptoms. AD spectrum consists of presymptomatic, early symptomatic, and symptomatic phase of dementia. At present, no pharmacotherapy exists to modify or reverse a course of AD, and only symptomatic treatments are available. Many elderly patients, diagnosed with multiple medical conditions (such as cardiovascular diseases, Type 2 diabetes mellitus, and cerebrovascular diseases) are at increased risk of the development of mild cognitive impairment (MCI), AD, and vascular dementia. Studies have revealed reduced rates of cognitive decline, in elderly patients, who were treated with centrally active angiotensin-converting enzyme inhibitors (ACE-Is) (that have an ability to cross the blood–brain barrier). This article reviews recently published literature, focused on possible protective influence of the centrally active ACE-Is, in the elderly population, at risk for cognitive decline. |
topic |
Alzheimer's disease angiotensin.converting enzyme inhibitors mild cognitive impairment renin.angiotensin system |
url |
http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2016;volume=62;issue=4;spage=242;epage=248;aulast=Rygiel |
work_keys_str_mv |
AT krygiel canangiotensinconvertingenzymeinhibitorsimpactcognitivedeclineinearlystagesofalzheimersdiseaseanoverviewofresearchevidenceintheelderlypatientpopulation |
_version_ |
1725838159200124928 |